Last reviewed 2026-04-20 · How we verify

PF04518600 (pf04518600)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Fatigue
• Blood bilirubin increased
• Abdominal pain
• Dry mouth
• Nausea
• Chills
• Nasopharyngitis
• Alanine aminotransferase increased
• Electrocardiogram U-wave abnormality
• Lipase increased
• Transaminases increased
• Urobilinogen urine increased

Key clinical trials

• Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (PHASE2)
• Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies (PHASE1, PHASE2)
• Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing (PHASE3)
• Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (PHASE2)
• Rituximab + Immunotherapy in Follicular Lymphoma (PHASE1)
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (PHASE1, PHASE2)
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
• Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.